List view / Grid view

Chronic lymphocytic leukaemia (CLL)


NICE asks Janssen to put ibrutinib forward for the CDF

1 June 2016 | By Victoria White, Digital Content Producer

The National Institute for Health and Care Excellence (NICE) has asked Janssen to set out a case for including its chronic lymphocytic leukaemia (CLL) drug ibrutinib (Imbruvica) in the Cancer Drugs Fund (CDF).

FDA grants Priority Review for venetoclax NDA

12 January 2016 | By Victoria White

The NDA for venetoclax is for the treatment of people with chronic lymphocytic leukaemia who have received at least one prior therapy, including those with 17p deletion...

Imbruvica Phase III combination data submitted to the FDA

13 November 2015 | By Victoria White

AbbVie has submitted a supplemental New Drug Application (sNDA) to the US Food and Drug Administration (FDA) for labelling considerations based on safety and efficacy results from the Phase III HELIOS trial investigating the use of Imbruvica (ibrutinib) plus bendamustine and rituximab (BR) versus placebo plus BR in relapsed or…